{"id":"W1464936406","doi":"10.1056/nejmoa1505270","title":"Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer","year":2015,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1586,"is_retracted":false,"has_abstract":true,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Fulvestrant; Palbociclib; Medicine; Internal medicine; Oncology; Breast cancer; Hazard ratio; Exemestane; Clinical endpoint; Neutropenia; Placebo; Cancer; Metastatic breast cancer; Clinical trial; Estrogen receptor; Confidence interval; Chemotherapy; Tamoxifen; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01997212785007568,"score_gpt":0.3116514899941887,"score_spread":0.2916793621441131,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}